Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Circulating tumor cells for tailoring BMP targeted therapies

Objectif

Gastro-intestinal (GI) cancers, including gastro-esophageal junctional (GEJC), gastric (GC), colorectal (CRC) and pancreatic cancer (PC) are devastating malignancies that annually affect over 2 million persons worldwide and lead to more than 600,000 deaths (Globocan 2012). Given the current trends, the incidence of GI cancer is expected to increase further. Conventional therapies include chemo- and radiation therapy combined with surgery. However, amongst cancer patients, GI cancer patients have one of the poorest outcomes with a 5-year survival ranging from only 60% for CRC to a mere 5% for PC
At the moment, important steps are being taken to implement the highly specific anti-BMP4 low molecular weight antibodies (Dwarfbodies ®; DB, recently developed by us) in the clinic as a novel treatment strategy for gastro-intestinal (GI) cancers. To enable optimal treatment a diagnostic compendium is required. The CTC4BMP project aims to deliver a blood based method for patient stratification to identify patients that will benefit from the BMP4 inhibiting Dwarfbody therapy.

Champ scientifique (EuroSciVoc)

Programme(s)

Thème(s)

Régime de financement

ERC-POC - Proof of Concept Grant

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) ERC-2016-PoC

Voir tous les projets financés au titre de cet appel

Institution d’accueil

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Contribution nette de l'UE
€ 150 000,00
Adresse
MEIBERGDREEF 15
1105AZ Amsterdam
Pays-Bas
Région
West-Nederland Noord-Holland Groot-Amsterdam
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 150 000,00

Bénéficiaires (1)